Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claims 1-14 (Canceled)

Claim 15 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], wherein at least two of the antigens ~~(1) to (5)~~ are expressed as a single polypeptide chain.

Claim 16 (Withdrawn-Currently Amended) The composition of claim 15 [[4]], wherein the ~~two recombinant polypeptides are~~ at least two of the antigens expressed as a single polypeptide chain and are selected from the group of antigens consisting of: the first antigen ~~a 'NadA' protein~~ & the second antigen ~~a 'NMB1870' protein~~; the first antigen ~~the 'NadA' protein~~ & the third antigen ~~a 'NMB2091' protein~~; the first antigen ~~the 'NadA' protein~~ & the fourth antigen ~~a 'NMB1030' protein~~; the first antigen ~~the 'NadA' protein~~ & the fifth antigen ~~a 'NMB2132' protein~~; the second antigen ~~the 'NMB1870' protein~~ & the third antigen ~~the 'NMB2091' protein~~; the second antigen ~~the 'NMB1870' protein~~ & the fourth antigen ~~the 'NMB1030' protein~~; the second antigen ~~the 'NMB1870' protein~~ & the fifth antigen ~~the 'NMB2132' protein~~; the third antigen ~~the 'NMB2091' protein~~ & the fourth antigen ~~the 'NMB1030' protein~~; the third antigen ~~the 'NMB2091' protein~~ & the fifth antigen ~~the 'NMB2132' protein~~; the fourth antigen ~~the 'NMB1030' protein~~ & the fifth antigen ~~the 'NMB2132' protein~~.

Claim 17 (Withdrawn-Currently Amended) The composition of claims 15 or 16, wherein the single polypeptide chain comprises a polypeptide of formula NH_2-A-X_1-L-X_2-B-COOH, wherein: X_1 is an amino acid sequence of one of the five antigens selected from the group consisting of the first antigen ~~the 'NadA' protein~~, the second antigen ~~the 'NMB1870' protein~~; the third antigen ~~the 'NMB2091' protein~~; the fourth antigen ~~the 'NMB1030' protein~~; and the fifth antigen ~~the 'NMB2132' protein~~ ; X_2 is an amino acid sequence of one of the five antigens selected from the group consisting

of the first antigen ~~the 'NadA' protein~~, the second antigen ~~the 'NMB1870' protein~~; the third antigen ~~the 'NMB2091' protein~~; the fourth antigen ~~the 'NMB1030' protein~~; and the fifth antigen ~~the 'NMB2132' protein~~ provided that X_1 is not the same as X_2; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; and B is an optional C-terminal amino acid sequence.

Claim 18 (Withdrawn-Currently Amended) The composition of claim 17, wherein X_1 is the third antigen ~~the NMB2091 protein~~ and X_2 is the second antigen ~~the NMB1870 protein~~.

Claim 19 (Withdrawn-Currently Amended) The composition of claim 17, wherein X_1 is the fifth antigen ~~the NMB2132 protein~~ and X_2 is the fourth antigen ~~the NMB1030 protein~~.

Claims 20-21 (Canceled).

Claim 22 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

Claim 23 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], further comprising a saccharide antigen from *Haemophilus influenzae* type B.

Claim 24 (Withdrawn) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, tetanus toxoid, CRM_{197} or *H.influenzae* protein D.

Claim 25 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], further comprising an antigen from *Streptococcus pneumoniae*.

Claim 26 (Currently Amended) The composition of claim 32 [[4]] further comprising a pharmaceutically acceptable carrier.

Claim 27 (Canceled).

Claim 28 (Withdrawn-Currently Amended) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims 32 [[4]], 15, or 16.

Claims 29-31 (Canceled).

Claim 32 (Currently Amended) [[The]] A composition comprising five meningococcal antigens ~~of claim 4~~, wherein the first antigen ~~NadA protein~~ comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 2, wherein the second antigen ~~NMB1870 protein~~ comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 3, wherein the third antigen ~~NMB2091 protein~~ comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 4, wherein the fourth antigen ~~NMB1030 protein~~ comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 5, and wherein the fifth antigen ~~NMB2132 protein~~ comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 6.

Claim 33 (Currently Amended) The composition of claim 32 [[4]], wherein the first antigen ~~NadA protein~~ comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 2, wherein the second antigen ~~NMB1870 protein~~ comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 3, and wherein the third antigen ~~NMB2091 protein~~ comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 4, wherein the fourth antigen ~~NMB1030 protein~~ comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 5, and wherein the fifth antigen ~~NMB2132 protein~~ comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 6.

Claim 34 (Currently Amended) The composition of claim 33 [[4]], wherein the NadA protein comprises SEQ ID 2, wherein the second antigen ~~NMB1870 protein~~ comprises SEQ ID 3, and wherein the third antigen ~~NMB2091 protein~~ comprises SEQ ID 4, wherein the fourth antigen ~~NMB1030 protein~~ comprises SEQ ID 5, and wherein the fifth antigen ~~NMB2132 protein~~ comprises SEQ ID 6.

Claim 35 (New) The composition of claim 33, wherein the first antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 2, wherein the second antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 3, and wherein the third antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 4, wherein the fourth antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 5, and wherein the fifth antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 6.

Claim 36 (New) The composition of claim 32, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.

Claim 37 (New) The composition of claim 33, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.

Claim 38 (New) The composition of claim 34, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.

Claim 39 (New) The composition of claim 35, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and

the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.